These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 30046162)

  • 1. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
    Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
    Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
    Walker BA; Wardell CP; Melchor L; Brioli A; Johnson DC; Kaiser MF; Mirabella F; Lopez-Corral L; Humphray S; Murray L; Ross M; Bentley D; Gutiérrez NC; Garcia-Sanz R; San Miguel J; Davies FE; Gonzalez D; Morgan GJ
    Leukemia; 2014 Feb; 28(2):384-390. PubMed ID: 23817176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.
    Bogun L; Koch A; Scherer B; Fenk R; Maus U; Bormann F; Köhrer K; Petzsch P; Wachtmeister T; Zukovs R; Dietrich S; Haas R; Schroeder T; Jäger P; Geyh S
    Blood Adv; 2024 May; 8(10):2575-2588. PubMed ID: 38241490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
    Dutta AK; Alberge JB; Sklavenitis-Pistofidis R; Lightbody ED; Getz G; Ghobrial IM
    Nat Rev Clin Oncol; 2022 Apr; 19(4):223-236. PubMed ID: 35017721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
    Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
    Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.
    Dutoit JC; Vanderkerken MA; Anthonissen J; Dochy F; Verstraete KL
    Eur Radiol; 2014 Nov; 24(11):2754-65. PubMed ID: 25106487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
    Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
    BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of progression in monoclonal gammopathy of undetermined significance.
    Rajkumar SV
    Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma.
    van de Donk NWCJ; Pawlyn C; Yong KL
    Lancet; 2021 Jan; 397(10272):410-427. PubMed ID: 33516340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
    Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P
    Ann Hematol; 2021 Feb; 100(2):437-443. PubMed ID: 33392702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.
    Thomsen H; Chattopadhyay S; Weinhold N; Vodicka P; Vodickova L; Hoffmann P; Nöthen MM; Jöckel KH; Langer C; Hajek R; Hallmans G; Pettersson-Kymmer U; Ohlsson C; Späth F; Houlston R; Goldschmidt H; Hemminki K; Försti A
    Leukemia; 2019 Jul; 33(7):1817-1821. PubMed ID: 30737484
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.